Patent Trial Over AstraZeneca Unit Soliris Drug Set For 2025
A London judge Thursday agreed to list a quarrel among three pharmaceutical companies over Alexion's patent for a drug that treats rare blood diseases for trial in early 2025, finding there...To view the full article, register now.
Already a subscriber? Click here to view full article